Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rayner

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|July 1, 1982
Circulating immune complex levels in patients with gestational trophoblastic neoplasiaA A Rayner, R Berkowitz, G Steele, et al.
The Journal of Hospital Infection|February 26, 2008
Mycobacteria and allograft heart valve banking: an international surveyR M Warwick, J G Magee, J P Leeming, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1991
Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721F E Halberg, S M LaRue, A A Rayner, et al.
American Journal of Medical Genetics. Part A|October 16, 2007
Posterior polymorphous corneal dystrophy is associated with TCF8 gene mutations and abdominal herniaAnthony J Aldave, Vivek S Yellore, Fei Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Molecular Vision|October 26, 2007
Identification of mutations in UBIAD1 following exclusion of coding mutations in the chromosome 1p36 locus for Schnyder crystalline corneal dystrophyVivek S Yellore, M Ali Khan, Nirit Bourla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Journal of the National Cancer Institute|June 1, 1983
Serial circulating immune complex levels and mitogen responses during progressive tumor growth in WF ratsM L Rodrick, G Steele, D S Ross, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|July 1, 1982
Circulating immune complex levels in patients with gestational trophoblastic neoplasiaA A Rayner, R Berkowitz, G Steele, et al.
The Journal of Hospital Infection|February 26, 2008
Mycobacteria and allograft heart valve banking: an international surveyR M Warwick, J G Magee, J P Leeming, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 1991
Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721F E Halberg, S M LaRue, A A Rayner, et al.
American Journal of Medical Genetics. Part A|October 16, 2007
Posterior polymorphous corneal dystrophy is associated with TCF8 gene mutations and abdominal herniaAnthony J Aldave, Vivek S Yellore, Fei Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Molecular Vision|October 26, 2007
Identification of mutations in UBIAD1 following exclusion of coding mutations in the chromosome 1p36 locus for Schnyder crystalline corneal dystrophyVivek S Yellore, M Ali Khan, Nirit Bourla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelinesK A Margolin, A A Rayner, M J Hawkins, et al.
Journal of the National Cancer Institute|June 1, 1983
Serial circulating immune complex levels and mitogen responses during progressive tumor growth in WF ratsM L Rodrick, G Steele, D S Ross, et al.
Pageof 16